Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Identification and characterization of the WFDC1 gene may aid in better understanding the potential role of this gene and ps20 in prostate biology and carcinogenesis.
|
10967136 |
2000 |
Malignant Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The WFDC1 gene was mapped by FISH analysis to human Chromosome (Chr) 16q24, an area of frequent loss of heterozygosity (LOH) previously identified in multiple cancers including prostate, breast, hepatocellular, and Wilms' tumor.
|
10967136 |
2000 |
Nephroblastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The WFDC1 gene was mapped by FISH analysis to human Chromosome (Chr) 16q24, an area of frequent loss of heterozygosity (LOH) previously identified in multiple cancers including prostate, breast, hepatocellular, and Wilms' tumor.
|
10967136 |
2000 |
Childhood Kidney Wilms Tumor
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The WFDC1 gene was mapped by FISH analysis to human Chromosome (Chr) 16q24, an area of frequent loss of heterozygosity (LOH) previously identified in multiple cancers including prostate, breast, hepatocellular, and Wilms' tumor.
|
10967136 |
2000 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We further investigated the role of WFDC1 as a tumour suppressor gene candidate in five hepatocellular cell lines and in tumours exhibiting LOH by means of mutation, promoter methylation and gene expression analysis.
|
12032731 |
2002 |
Hepatocarcinogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest a minor role, if any, of WFDC1 in hepatocarcinogenesis.
|
12032731 |
2002 |
Liver carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The WFDC1 gene maps in human chromosome 16q24, an area of frequent loss of heterozygosity (LOH) in several tumour types, in particular in hepatocellular carcinoma (HCC).
|
12032731 |
2002 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
To address the potential effects of ps20 in a tumor microenvironment, we used the DRS model to evaluate both angiogenesis and tumorigenesis of tumors generated under either ps20 or control conditions.
|
14522910 |
2003 |
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model.
|
14522910 |
2003 |
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model.
|
14522910 |
2003 |
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
To address the potential effects of ps20 in a tumor microenvironment, we used the DRS model to evaluate both angiogenesis and tumorigenesis of tumors generated under either ps20 or control conditions.
|
14522910 |
2003 |
Duane Retraction Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, we show that ps20 mRNA synthesis is induced by TGF-beta1, a known regulator of endothelial cell-pericyte interactions and of stromal cell-induced angiogenesis in DRS tumors.
|
14522910 |
2003 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We, therefore, propose that WFDC1/ps20 may not be a classical tumor suppressor gene, but might play a role in the maintenance of the normal extra cellular matrix milieu in the prostate.
|
15305342 |
2004 |
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We, therefore, chose to examine WFDC1/ps20 for mutations and expression changes in prostate cancer.
|
15305342 |
2004 |
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We, therefore, chose to examine WFDC1/ps20 for mutations and expression changes in prostate cancer.
|
15305342 |
2004 |
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Quantitative RT-PCR demonstrated significant down regulation of WFDC1/ps20 in prostate tumors.
|
15305342 |
2004 |
melanoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of novel tumor suppressors in malignant melanoma.
|
17145863 |
2006 |
melanoma
|
0.310 |
PosttranslationalModification
|
disease |
BEFREE |
Furthermore, we show that promoter hypermethylation accounts for the silencing of the WFDC1 gene in 20% of the melanoma cell lines examined.
|
19488830 |
2009 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Gene expression microarray analysis and further expression validation suggests that the Dickkopf-1 (Dkk1) gene is up-regulated in WFDC1 over-expressing cell lines, suggesting that the tumor suppressive function of WFDC1 may be partially a result of up-regulated Dkk1 gene expression, which is known to be a potent inhibitor of the Wnt signaling pathway.
|
19488830 |
2009 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Taken together, our data suggest an important role for WFDC1 in inhibiting proliferation of both tumors and senescent cells.
|
18842679 |
2009 |
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Modulated expression of WFDC1 during carcinogenesis and cellular senescence.
|
18842679 |
2009 |
Fibrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of WFDC1 inhibited the growth rate of the fibrosarcoma HT1080 cell line.
|
18842679 |
2009 |
Adult Fibrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of WFDC1 inhibited the growth rate of the fibrosarcoma HT1080 cell line.
|
18842679 |
2009 |
Alcohol consumption
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene-alcohol interactions identify several novel blood pressure loci including a promising locus near SLC16A9.
|
24376456 |
2013 |